40 results about "Eclampsia preeclampsia" patented technology

The invention discloses application of umbilical cord mesenchymal stem cell-derived exosome in preparing drug or preparation for treating preeclampsia, in particular relates to application of treating preeclampsia by extracting exosome through umbilical cord mesenchymal stem cells of humans. The exosome can effectively alleviate hypertension and proteinuria of preeclampsia and glomerulonephritis, reduce inflammatory response in placenta, and promote fetal development. This kind of exosome has the advantages of convenience in storage and transport and provides a new strategy for treating related diseases of refractory inflammations of preeclampsia.

The invention disclosed application of FAM127A in a pregnancy disease. Specifically, the disease is pre-eclampsia. The expression of FAM127A is down-regulated in a pregnant womon with pre-eclampsia. It is found through large sample verification that the gene has higher positive detection rate, and it is proposed that the gene can be applied to clinical diagnosis of pre-eclampsia. By overexpressingthe FAM127A in trophoblast cells, it is found that the proliferation ability and invasion ability of the trophoblast cells are changed, and it is prompted that the FAM127A can serve as a potential target for the treatment of pre-eclampsia.

The invention discloses a placenta-derived endogenous polypeptide and application thereof. The invention relates to a placenta tissue endogenous polypeptide APEP1 (Anti-Pre-eclampsia peptide 1). The amino acid sequence of the placenta tissue endogenous polypeptide APEP1 (Anti-Pre-eclampsia peptide 1) is as shown in SEQ ID NO. 1. The polypeptide APEP1 can promote the proliferation capacity of placental trophoblasts. The human placenta tissue endogenous polypeptide APEP1 can be used for preparing drugs or reagents for promoting placenta trophoblast cell proliferation capacity of preeclampsia patients, and is expected to provide a novel treatment strategy for preeclampsia treatment.

The invention relates to the field of molecular diagnosis and medical treatment, in particular to an application of miR-196a-5p as a placental implantable disease marker. The miR-196a-5p can be used for diagnosis of placental implantable diseases, or used for distinguishing placental implantable diseases from preplacenta and preeclampsia, and has important clinical application value.

The invention discloses the application of a novel polypeptide for improving placental dysfunction in preeclampsia, relates to the related field of medicine, and solves the problem that most drugs in the prior art for improving placental dysfunction in preeclampsia have certain toxic and side effects on the mother and fetus. The application of the polypeptide is in the preparation of a medicine or a medicament for improving placental dysfunction in preeclampsia; the polypeptide sequence is Ac-RFAACAA-COOH.

The invention discloses test paper for quickly screening late onset severepre-eclampsia. The test paper for quickly screening late onset severepre-eclampsia comprises optional test paper for detectingthe APELA concentration in blood or urine. The invention also discloses a kit for screening late onset severepre-eclampsia. The kit comprises an optional reagent for detecting the APELA concentrationin blood or urine. The invention also discloses application of the test paper for detecting the APELA concentration in blood or urine in preparing the test paper for screening late onset severepre-eclampsia. The invention also discloses application of the reagent for detecting the APELA concentration in blood or urine in preparing a reagent for screening late onset severepre-eclampsia. Accordingto the test paper and the kit for quickly screening late onset severepre-eclampsia disclosed by the invention, only blood and urine of a patient need to be acquired, and whether the patient is suffered from late onset severepre-eclampsia or not can be screened, so that the test paper and the kit can be used for noninvasively, effectively and quickly examining and screening late onset severepre-eclampsia, and are convenient to use and favorable in clinic application prospect.

The invention belongs to the fields of genetic engineering and clinical medicine, and discloses a related serum microribonucleic acid marker for human severe preeclampsia and application of the marker. The marker is selected from more of hsa-miR-193a-5p, hsa-miR-424 and hsa-miR-10a. The marker has the specificity and sensitivity on a sufferer with severe preeclampsia, and can be used for preparing a diagnosis or monitoring kit for severe preeclampsia.

The invention discloses that a VWCE gene can be used as a molecular marker for preeclampsia diagnosis. The experiment of the invention proves that the expression of the VWCE gene is high in placenta tissues of a preeclampsia patient in comparison with that in normal placenta tissues. The invention also discloses that the VWCE gene can be used for preparation of a drug for treating preeclampsia. The research results provided by the invention provide a new preeclampsia clinical diagnosis method, and also provide a new drug target for treating preeclampsia.

The invention belongs to the field of biomedicine and discloses application of HCST (hematopoietic cell signal transducer) gene as a target to diagnose and treat preeclampsia. It is proved by the experiment that HCST gene has significant differences of expression in normal placenta tissue and preeclampsia placenta tissue. According to relevancy of HCST gene to preeclampsia, HCST gene may be used as a novel molecular marker to clinically diagnose preeclampsia and may also be used as a novel target to preeclampsia drugs.

A gene combination for predicting preeclampsia risk, a preeclampsia risk prediction model and a construction method thereof belong to the field of biomedicine. The invention uses gene polymorphism detection to screen out 499 susceptibility genes, and combines 46 clinical Detection data, using computer deep learning method to prepare a preeclampsia risk prediction model, can predict the risk of preeclampsia. The model design of the present invention mainly relies on the random forest algorithm in computer machine learning, and the gene polymorphism detection results and clinical detection data are converted into digital feature vectors required for building the model, and the number of decision trees in the random forest is set to 1000 , the training process adopts the random sampling method with replacement to construct the training set, and uses the out-of-bag error rate samples (samples not drawn) as the test set to calculate the error rate of the model.

The invention disclosed application of FAM127A in a pregnancy disease. Specifically, the disease is pre-eclampsia. The expression of FAM127A is down-regulated in a pregnant womon with pre-eclampsia. It is found through large sample verification that the gene has higher positive detection rate, and it is proposed that the gene can be applied to clinical diagnosis of pre-eclampsia. By overexpressingthe FAM127A in trophoblast cells, it is found that the proliferation ability and invasion ability of the trophoblast cells are changed, and it is prompted that the FAM127A can serve as a potential target for the treatment of pre-eclampsia.

The invention discloses application of ZNF770 gene as a diagnostic treatment target for preeclampsia. Accordingly, ZNF770 can be used to develop products to diagnose preeclampsia and drugs to treat preeclampsia. Study results of herein provide theoretical basis for clinicians to formulate personalized treatment plans and provide novel pharmaceutical targets to develop preeclampsia drugs.

The invention discloses a diagnosis and treatment target-PLEK gene of preeclampsia. Whether a subject has the preeclampsia is judged or whether the subject has the risk of being suffered from preeclampsia is diagnosed through detecting the content of a PLEK gene and an expression product thereof in a placental tissue of the subject. Furthermore, a proliferation index of a preeclampsia cell, whichis cultured in vitro, is researched and proves that the PLEK gene is used as a medicine target for treating the preeclampsia.

The invention, which belongs to the biomedicine field, discloses application of a labeling reagent of long-chain fatty acid coenzyme A ligase 1 in preparation of a kit for diagnosing whether a pregnant woman suffers from preeclampsia or predicting whether a pregnant woman has the risk of suffering from preeclampsia. The invention further discloses a kit for diagnosing whether a pregnant woman suffers from preeclampsia or predicting whether the pregnant woman has the risk of suffering from preeclampsia or not. The kit comprises a labeling reagent of the long-chain fatty acid coenzyme A ligase 1. Therefore, a novel biomarker for diagnosis and early warning of the preeclampsia of hypertensive disorder complicating pregnancy and has the important clinical value.